Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

View Full Paper
Ask AI
Bookmark
Share

Authors

ÁSÁngel SernaLMLaura MagnanoPVPedro José Paúl Vidaller

Discussion

Loading...

Member takes

Overview

Retrospective analysis identified predictive models for cytokine release syndrome in non-Hodgkin lymphoma patients, suggesting improved hospital resource allocation.

Key Points

  • Cytokine release syndrome was observed in 46% of patients receiving bispecific antibodies during treatment.
  • Key metrics showed IPI/FLIPI score and lactate dehydrogenase levels significantly predict severe CRS risk.
  • Retrospective analysis of 164 patients with non-Hodgkin lymphoma provided insights into risk factors for CRS.
  • This model may enhance decision-making regarding the hospitalization of lymphoma patients during therapy.

Cite This Study

Serna et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deeahttps://doi.org/10.1182/blood-2025-3737
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium2025
  2. 2CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma2025
  3. 3Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.2025
  4. 4Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts2025 · 1 citations
  5. 5Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort2025